Transgene SA entered its first product-development deal, a collaboration worth up to €218 million (US$293) on its late-stage therapeutic vaccine against human papillomavirus-related diseases. (BioWorld Today)
Acadia Pharmaceuticals Inc. capitalized on the recent jump in its shares, pricing an $89.1 million public offering. The San Diego-based company sold 5.75 million shares at $15.50 per share, an offering expected to net $83.5 million. Underwriters have a 30-day overallotment option on 862,500 additional shares, which would add about $13.4 million to the gross proceeds if exercised. (BioWorld Today)
Acadia Pharmaceuticals Inc. capitalized on the recent jump in its shares, pricing an $89.1 million public offering. The San Diego-based company sold 5.75 million shares at $15.50 per share, an offering expected to net $83.5 million. Underwriters have a 30-day overallotment option on 862,500 additional shares, which would add about $13.4 million to the gross proceeds if exercised. (BioWorld Today)
